File(s) under permanent embargo
Phase II trial of alternating osimertinib with gefitinib in patients with EGFR-T790M mutation-positive advanced non-small cell lung cancer (Oscillate).
journal contribution
posted on 2023-03-17, 05:06 authored by Ann LivingstonePhase II trial of alternating osimertinib with gefitinib in patients with EGFR-T790M mutation-positive advanced non-small cell lung cancer (Oscillate).